Medicare patients get drug-price relief; insurers lose rebate windfall
H.R. 5197 — Protect Beneficiaries from Middlemen Act · Filed by Nicole Malliotakis (R-NY) · Introduced Sep 8, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps what Medicare Part D beneficiaries pay out-of-pocket for prescription drugs at the 'net price'—the actual amount insurers pay pharmacies after rebates and discounts—rather than the higher list price. Starting in 2027, patients cannot be charged more than what the plan actually paid for the drug (or the pharmacy's cash price, whichever is lower). The bill targets 'middlemen' (pharmacy benefit managers and insurers) who currently pocket rebates while charging patients based on inflated list prices.
Why we flagged it
The bill's operative mechanism is a price-transparency mandate: it requires that patient cost-sharing reflect actual net prices paid by plans, not inflated list prices. This is fundamentally a patient-protection measure that constrains insurer and PBM pricing discretion.
What the text implies
- Rebate structures may shift: PBMs and manufacturers may renegotiate rebate agreements or move rebates into other forms (e.g., direct manufacturer payments to plans) to maintain revenue while complying with the net-price cap.
- Plan design incentives may change: insurers may respond by narrowing formularies, increasing prior-authorization requirements, or steering patients toward lower-cost drugs to manage the impact of lower copay revenue.
The full analysis lists 5 implications of this text.
Who stands to gain
Medicare Part D beneficiaries (direct cost savings); Potentially: manufacturers (if rebate reductions lead to higher net prices or list prices)